Hydrocortisone Activase (Hydrocortisone)

Hydrocortisone Activase is prescribed for conditions where reduction of inflammation or immune response is required.

• Management of mild to moderate inflammatory skin disorders such as eczema or dermatitis.
• Treatment of adrenal insufficiency when oral glucocorticoid replacement is indicated.
• Short‑term therapy for allergic reactions affecting the gastrointestinal tract.
• Adjunctive therapy for certain autoimmune conditions under specialist guidance.
• Supportive care in severe asthma exacerbations when systemic corticosteroid is needed.
• Temporary relief of inflammatory joint pain associated with rheumatic disorders.

• Hydrocortisone Activase exerts its pharmacologic effect by binding to intracellular glucocorticoid receptors. The drug‑receptor complex translocates to the nucleus where it modulates gene transcription, up‑regulating anti‑inflammatory proteins such as annexin‑1 and down‑regulating pro‑inflammatory cytokines like interleukin‑1 and tumor necrosis factor‑α. This genomic action reduces leukocyte migration, capillary permeability, and fibroblast proliferation, leading to the observed anti‑inflammatory and immunosuppressive outcomes in the body.

Adverse reactions to Hydrocortisone Activase can vary in frequency and severity, ranging from mild skin changes to more serious systemic effects.

Common

• Transient increase in blood glucose levels.
• Mild gastrointestinal discomfort or nausea.
• Localized skin thinning or bruising at sites of prolonged exposure.
• Insomnia or mood changes such as irritability.

Serious

• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis leading to adrenal insufficiency.
• Severe allergic reactions including rash, angioedema, or anaphylaxis.
• Osteoporosis or increased fracture risk with long‑term use.
• Significant fluid retention causing edema or hypertension.

Before initiating Hydrocortisone Activase, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active infections, as systemic glucocorticoids can worsen bacterial, viral, or fungal diseases.
• Review patient history for diabetes, hypertension, or osteoporosis, which may be exacerbated.
• Use the lowest effective dose for the shortest duration required.
• Monitor growth in pediatric patients receiving prolonged therapy.
• Avoid abrupt discontinuation; taper gradually to prevent adrenal crisis.
• Caution in patients with known hypersensitivity to corticosteroids.

Hydrocortisone Activase may interact with other medicines, altering its efficacy or increasing adverse effects.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce plasma concentrations.
• Simultaneous administration of systemic anticoagulants, which can increase bleeding risk due to mucosal thinning.

Use with caution

• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) may raise gastrointestinal ulcer risk.
• Co‑administration with vaccines, especially live attenuated vaccines, may diminish immune response.
• Use alongside other glucocorticoids can amplify systemic corticosteroid effects.
• Interaction with diuretics may exacerbate fluid retention and electrolyte imbalance.